First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Open to males ages 18 years and up

• Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate.
• Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 and life expectancy of ≥3 months (≥12 weeks).
• Progression on ADT and >=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane-based chemotherapy regimens. Participants should have received all approved standard-of-care therapies for which they are eligible, including biomarker directed therapy, in accordance with current clinical guidelines, unless a documented contraindication or another justified medical reason precluded their use.

• Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma.
• Impaired cardiac function or clinically significant cardiac disease.
• Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality.
• Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion/exclusion criteria apply.